InvestorsHub Logo
Followers 7
Posts 299
Boards Moderated 0
Alias Born 01/07/2010

Re: Titan V post# 35708

Monday, 08/29/2016 3:17:27 PM

Monday, August 29, 2016 3:17:27 PM

Post# of 48316
i'm admittedly basing my thoughts on very little DD but i was curious why INO had success securing BP partners AZN/Medimmune, Roche (granted it was dropped) and NCI for it's electroporation based therapies while ONCS has been on it's own so far. i doubt it is because INO develops its EP-tech in-house while ONCS outsources EP-tech while focusing on its gene therapy. is it because INO's indications suited BP better while ONCS's indication is a hard-sell or because ONCS's trials are not late stage enough? i doubt both. apologies if my ruminations stem from bad info/assumptions i have made. thanks for all your posts.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCSQ News